DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for van Maldergem syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleVan Maldergem syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for van maldergem syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
FAT atypical cadherin 4 (FAT4) — FAT4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet cacdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8EGW · 2.3 Å · ligand CACODYLATE ION (CAC). Experimental structure, not a prediction.
What the evidence adds up to
Van Maldergem syndrome is a rare genetic condition defined by biallelic variants in FAT4 or DCHS1. A 2018 review of 11 patients with VMS and 40 patients with Hennekam syndrome, both linked to FAT4 variants, found that the two disorders share a typical facial appearance and mild to moderate intellectual disability but differ in key features: VMS includes neonatal hypotonia, feeding problems, hearing loss, tracheal anomalies, and osteopenia, while Hennekam syndrome includes lymphedema. The same review reported two new siblings with VMS and one girl with Hennekam syndrome, all carrying FAT4 variants, and concluded that despite some overlapping signs, the differences in main symptoms are marked for affected individuals.
The original 1992 description of the syndrome in a single girl noted facial abnormalities (telecanthus, epicanthus, broad flattened nose, large inverted W-shaped mouth, malformed ears), hand malformations (camptodactyly, clinodactyly, interdigital webbing, joint hyperlaxity), and mental retardation. The authors suggested this might represent a new syndrome or an extreme variant of known conditions such as Pashayan-Pruzansky syndrome or fetal alcohol syndrome. No treatment or intervention was proposed.
A 2019 case report described a three-year-old boy with both congenital adrenal hyperplasia and suspected Van Maldergem syndrome, supported by a novel likely pathogenic variant in a known gene. The authors emphasised that coexisting genetic conditions are encountered infrequently, that whole exome sequencing increasingly reports variants of unknown significance, and that confirming both diagnoses and performing functional studies is necessary before exploring any relationship between them.
No clinical trials, no drug interventions, and no survival or response rate data exist for Van Maldergem syndrome. What is missing is any systematic natural history study, any patient registry large enough to stratify by genotype, and any funding for preclinical work that might identify a druggable pathway.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part A · 2018 · 28 citations · open access
Van Maldergem syndrome and Hennekam syndrome: Further delineation of allelic phenotypes
AbstractBiallelic variants in FAT4 are associated with the two disorders, Van Maldergem syndrome (VMS) (n = 11) and Hennekam syndrome (HS) (n= 40). Both conditions are characterized by a typical facial gestalt and mild to moderate intellectual disability, but differ in the occurrence of neonatal hypotonia and feeding problems, hearing loss, tracheal anomalies, and osteopenia in VMS, and lymphedema in HS. VMS can be caused by autosomal recessive variants in DCHS1 as well, and HS can also be caused by autosomal recessive variants in CCBE1 and ADAMTS3. Here we report two siblings with VMS and one girl with HS, all with FAT4 variants, and provide an overview of the clinical findings in all patients reported with FAT4 variants. Our comparison of the complete phenotypes of patients with VMS and HS indicates a resemblance of several signs, but differences in several other main signs and symptoms, each of marked importance for affected individuals.
Mental retardation with blepharo‐naso‐facial abnormalities and hand malformations: a new syndrome?
AbstractVan Maldergem L, Wetzburger C, Verloes A, Fourneau C, Gillerot Y. Mental retardation with blepharo‐naso‐facial abnormalities and hand malformations: a new syndrome. Clin Genet 1992:41: 22–24. A syndrome involving facial abnormalities (telecanthus, epicanthus, broad flattened nose, large inverted W‐shaped mouth and malformed ears), malformed extremities (camptodactyly, clinodactyly, interdigital webbing and joint hyperlaxity) and mental retardation is described in a girl at birth and at 11 years old. A comparison with Pashayan‐Pruzansky syndrome, fetal alcohol syndrome, VATER association, Marden‐Walker syndrome and Tel‐Hashomer syndrome is discussed. We suggest this patient represents a new malformation syndrome or an extreme pheno‐typic variant of one of the above‐mentioned syndromes.
Sudanese Journal of Paediatrics · 2019 · 4 citations
Coexistence of genetic conditions: Exploring a possible relationship
AbstractWe report on a 3-year-old boy who has congenital adrenal hyperplasia and a suspected Van Maldergem syndrome, another genetic condition, with the classic phenotype seen in our patient. The latter diagnosis was supported by a genetic test that showed a novel and likely pathogenic variant in a previously described gene of the syndrome. Paediatricians do encounter such a challenge of coexisting genetic conditions albeit infrequently, and advanced genetic analysis, example whole exome sequencing, increasingly report variants of unknown significance with a variable degree of potential pathogenicity. The treating physician needs to follow a systematic approach and entertain thorough literature search and brainstorming in order to prove or disprove any possible relationship between coexisting genetic conditions. The first step should be confirming the existence of the two conditions in the first place. In addition, when family segregation is unable to confidently make a sensible conclusion in such cases, a clinician should proceed to advanced functional studies to confirm pathogenicity. Then, one can explore further any hidden relationship between coexisting and possibly clinically-related genetic conditions.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
